Ovid Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Ovid Therapeutics

13/03/2023 13:00

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 18 cents per share.
    * Revenue was $46.28 thousand​; analysts expected zero. 
    * Ovid Therapeutics Inc's reported EPS for the quarter was a
loss
of 16 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Ovid Therapeutics Inc shares had risen by 7.5% this
quarter.
    * The company reported a quarterly loss of $11.51 million.
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 13 at 01:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.18          -0.16          Beat
 Sep. 30 2022      -0.21          -0.17          Beat
 Jun. 30 2022      -0.25          -0.21          Beat
 Mar. 31 2022      -0.21          -0.23          Missed